Will Patients with Kidney Disease Eventually Receive New Drug Class?

Published Date: 21 Oct 2023

Just over 2 years ago, dapagliflozin became the first SGLT2 inhibitor to be authorized for CKD alone, but uptake has been slow. Could change be sparked by a similar label gain for empagliflozin and a fresh suggestion?

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot